SUFFOLK, United Kingdom, Aug. 28, 2002 (PRIMEZONE) -- GeneMedix plc (LSE:GMX) ("GeneMedix" or "the Company"), the U.K. generic biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, announces its results for the 6 months to 31 May 2002. GeneMedix is involved in the development and manufacture of therapeutic proteins using recombinant DNA technology and novel cell culture.
To view the full press release please click on the link below:http://reports.huginonline.com/871690/107484.htm